More than 80% of pharmaceutical and biologics companies are completing their postmarketing studies and regulatory obligations in a timely manner.
More than 80% of pharmaceutical and biologics companies are completing their postmarketing studies and regulatory obligations in a timely manner. The finding is a result of a new FDA study performed under contract with Booz Allen Hamilton and supported by Congress that reviewed 1531 open postmarketing studies submitted by pharmaceutical firms.
"New resources and directives from Congress have allowed us to complete this long-desired review," said Janet Woodcock, Director of the FDA’s Center for Drug Evaluation and Research in press statement. "The data indicate that makers of approved drugs and biologics are generally meeting their regulatory obligations and are on track with their studies. To date, we have not identified any previously unknown serious safety issues from the submitted final study reports."
The study included recommendations as to how companies may improve the quality of the information they submit to the FDA, the timeliness of the FDA review and the accuracy of the FDA’s databases, including:
The agency says it will continue to work with Booz Allen Hamilton to complete its review of all submitted reports in a timely manner.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.